|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Descriptive Information Fields | |||||
| Brief Title † | Investigation of V520 in an HIV Vaccine Proof-of-Concept Study | ||||
| Official Title † | |||||
| Brief Summary | This study will test the safety and efficacy of V520 HIV vaccine. Efficacy will be measured by either prevention of HIV infection or control of HIV viral load in subjects who become HIV infected. |
||||
| Detailed Description | |||||
| Study Phase | Phase II | ||||
| Study Type † | Interventional | ||||
| Study Design † | Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study | ||||
| Primary Outcome Measure † | |||||
| Secondary Outcome Measure † | |||||
| Condition † | AIDS HIV Infections |
||||
| Intervention † | Biological: V520 | ||||
| MEDLINE PMIDs | |||||
| Links | Click here for more information about this trial ![]() |
||||
| Recruitment Information Fields | |||||
| Recruitment Status † | Terminated | ||||
| Enrollment † | |||||
| Start Date † | December 2004 | ||||
| Completion Date | |||||
| Eligibility Criteria † | Inclusion Criteria:
|
||||
| Gender | Both | ||||
| Ages | 18 Years to 45 Years | ||||
| Accepts Healthy Volunteers | Yes | ||||
| Contacts †† | |||||
| Location Countries † | |||||
| Administrative Information Fields | |||||
| NCT ID † | NCT00095576 | ||||
| Organization ID | 2004_091 | ||||
| Secondary IDs †† | |||||
| Study Sponsor † | Merck | ||||
| Collaborators †† | |||||
| Investigators † |
|
||||
| Information Provided By | Merck | ||||
| Verification Date | September 2007 | ||||
| First Received Date † | November 5, 2004 | ||||
| Last Updated Date | September 26, 2007 | ||||